Rodolfo Savica, MD, PhD, Mayo Clinic, Rochester, MN, provides an insight into our current understanding of early-onset Parkinson’s disease (PD). When considering early-onset PD, not much data is available; indeed, not even the clinical definition and age cut-off are established. To help movement disorders specialists and neurologists navigate the management of early-onset PD patients, the Movement Disorders Society launched a task force on early-onset PD. The goals of this task force include the development of a clear clinical and scientific definition of early-onset PD as well as identifying social, societal, and individual needs of patients with early-onset PD. Since early-onset PD affects people in the years of employment and fertility, it carries an additional set of social, societal, and personal consequences. Additionally, fighting dogmas such as that levodopa should not be used in early-onset PD or associating early-onset PD with familial history is also an objective of the recent task force. This interview took place at the 2022 International Congress of Parkinson’s disease and Movement Disorders in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
